Abstract
The relationship between obstructive sleep apnea (OSA) and endocrine and metabolic disease is unequivocal. OSA, which is characterized by intermittent hypoxia and sleep fragmentation, leads to and exacerbates obesity, metabolic syndrome, and type 2 diabetes (T2D) as well as endocrine disturbances, such as hypothyroidism and Cushing syndrome, among others. However, this relationship is bidirectional with endocrine and metabolic diseases being considered major risk factors for the development of OSA. For example, polycystic ovary syndrome (PCOS), one of the most common endocrine disorders in women of reproductive age, is significantly associated with OSA in adult patients. Several factors have been postulated to contribute to or be critical in the genesis of dysmetabolic states in OSA including the increase in sympathetic activation, the deregulation of the hypothalamus-pituitary axis, the generation of reactive oxygen species (ROS), insulin resistance, alteration in adipokines levels, and inflammation of the adipose tissue. However, probably the alterations in the hypothalamus-pituitary axis and the altered secretion of hormones from the peripheral endocrine glands could play a major role in the gender differences in the link between OSA-dysmetabolism. In fact, normal sleep is also different between men and women due to the physiologic differences between genders, with sex hormones such as progesterone, androgens, and estrogens, being also connected with breathing pathologies. Moreover, it is very well known that OSA is more prevalent among men than women, however the prevalence in women increases after menopause. At the same time, the step-rise in obesity and its comorbidities goes along with mounting evidence of clinically important sex and gender differences. Metabolic and cardiovascular diseases, seen as a men's illness for decades, presently are more common in women than in men and obesity has a higher association with insulin-resistance-related risk factors in women than in men. In this way, in the present manuscript, we will review the major findings on the overall mechanisms that connect OSA and dysmetabolism giving special attention to the specific regulation of this relationship in each gender. We will also detail the gender-specific effects of hormone replacement therapies on metabolic control and sleep apnea.
Introduction
Obstructive sleep apnea (OSA), the most common sleep disorder, is characterized by disturbances in sleep patterns namely arousals, snoring, and recurrent episodes of cessation of breathing airflow (apnea) or airflow reduction (hypopnea) leading to excessive daytime somnolence, difficulty in concentrating, or headaches. OSA severity is classified based on the apnea-hypopnea index (AHI) and oxygen desaturation levels, which are measured in a polysomnography study. Based on AHI, the number of apneas or hypopneas per hour, OSA is clinically classified as: none/minimal: AHI < 5 per hour; mild: AHI ≥ 5, but < 15 per hour; moderate: AHI ≥ 15, but < 30 per hour; and severe: AHI ≥ 30 per hour. There are no generally accepted classifications for OSA severity based on oxygen desaturation, although reductions to not <90% are considered mild; reductions to the 80–89% range are usually considered moderate, and below 80% are severe (Hudgel, 2016).
OSA is a severe public health disease affecting 3–7% of men and 2–5% of women (Punjabi, 2008; Fietze et al., 2019). Gender differences in sleep disorders prevalence have been identified in many study-based population studies, both clinical and community-based studies, leading these disorders to be classified as a male disorder. In the first report on sleep disorder prevalence, published in the 1990s and based on the Wisconsin Cohort Study (WSCS), sleep-disordered breathing prevalence characterized as an AHI of 5 or higher was described to be 9% for women and 24% for men (Young et al., 1993). Many other studies following this one maintained the same trend or even increased the gender difference in sleep disorders, like the HypnoLaus Sleep Cohort study (Heinzer et al., 2015). This extensive study assessing the prevalence of sleep-disordered breathing in a population-based sample using the most recent polysomnographic recording techniques at the time, recorded a sleep-disordered breathing prevalence ranging from 15 to 40% in men and 4 to 35% in women, depending on the clinically defined categories (mild, moderate, and severe) or age (< or > from 60 years old) (Heinzer et al., 2015). However, the high prevalence in men compared with women based on the clinical data, which can be as high as a 90–1 male:female ratio, decreases when community-based studies are analyzed. For example, Redline and colleagues using community-based data showed that sleep apnea prevalence in women, even though lower than in men, is markedly higher than the prevalence ratio found in clinical samples which can be explained by the clinical under-recognition of symptoms of apneic activity in women (Redline et al., 1994). Also, the higher prevalence of OSA in men compared to women has been justified by cultural, anthropometric, and clinical differences between genders (Bonsignore et al., 2019; Fietze et al., 2019). For example, OSA tends to appear in older women in comparison to men, probably due to the protection provided by female-specific hormones like progesterone, which are lost when women achieve menopausal age. Also, differences in upper airway anatomy and function and differences in obesity incidence and fat distribution (more central in men and more peripheral in women) between genders justify the higher prevalence of OSA in men (Bonsignore et al., 2019). Despite the difference in reported prevalence, women represent 40 to 50% of patients coming to sleep clinics (Franklin et al., 2013). OSA typically manifests in women as a lower AHI, shorter apneic episodes, a lower proportion of supine OSA, and clustering of apnea during rapid eye movement (REM) sleep (Kapsimalis and Kryger, 2002) (Table 1). However, for the same AHI in a severe state females present higher severe oxygen desaturation justifying higher symptoms regarding reported sleepiness and more frequent recurrence to sleep clinics (Bonsignore et al., 2019). Additionally, leptin levels are higher in women which can give some protection even in an obese state, while other endocrinologic dysfunctions like hypothyroidism are highly prevalent in women, which may per se induce OSA (Bonsignore et al., 2019).
Table 1
| Clinical features of OSA in females |
|---|
| Shorter and less collapsible upper airway |
| Lower central chemoresponsiveness |
| Less respiratory drive instability |
| Progesterone stimulation of ventilation |
| Lower apneic thresholds in premenopause |
| Less intense snoring |
| Lower A/HI overall |
| Shorter apneic episodes |
| Higher frequency of REM-related OSA |
| Longest apneas associated with more severe arterial oxygen desaturation |
| Longer sleep but more disturbed |
Clinical features of obstructive sleep apnea (OSA) in females.
Cardiometabolic diseases, namely hypertension, metabolic diseases, cardiovascular and cerebrovascular diseases, are common in OSA, being risk factors for its development (Jean-Louis et al., 2008). Additionally, several studies showed that metabolic syndrome is highly prevalent in OSA patients and closely associated with chronic intermittent hypoxia (CIH) (Grunstein, 1996; Gambineri et al., 2003). However, the different prevalence of these metabolic alterations in men vs. women and/or aging in each gender justify, at least in part, the differences in OSA prevalence and the effects of chronic intermittent hypoxia, as well as the differences in the efficacy of the available OSA treatments in each gender. Moreover, it is fundamental to discuss the gender differences in both OSA and metabolic syndrome prevalence from the perspective of the hormonal differences between genders as well as the hormone replacement therapy (HRT) efficacy between men and women.
Altogether, this review will discuss the many conflicting aspects regarding similarities and differences between men and women in what concerns metabolic diseases and OSA prevalence. More importantly the main objective of this discussion will be to highlight how metabolism dysfunction affects OSA and vice-versa in order to better understand differences in the impact of therapies for both pathologies and the personalization of those therapies based on gender, age, body composition, and comorbidities.
Osa-Dysmetabolism Link
Obesity, a major factor risk identified for the metabolic syndrome-related dysfunctions, has also been associated with the development and progression of OSA (Conde et al., 2014; Bonsignore et al., 2019), especially with visceral obesity, showing a link not only based on the anatomic/mechanical impact but also on the metabolic activity dysfunction (Çuhadaroglu et al., 2009). In fact, a modest decrease in body weight promotes a significant improvement in polysomnographic parameters and sleep patterns, and bariatric surgery, which promotes a huge decrease in body weight, when performed in obese patients, promotes large improvements in both OSA and diabetes-related parameters (Miras et al., 2018). Sleep apneic patients, when compared with obese controls, had a significantly higher amount of visceral fat, which correlates with O2 saturation and AHI levels. No correlations were found between subcutaneous fat and AHI (Vgontzas et al., 2005; Çuhadaroglu et al., 2009). However, the link between obesity and OSA is not unidirectional, as OSA can also per se promote body weight gain. This dual link is supported not only by weight gain but also by the multiple endocrine abnormalities that are involved in the development of fat accumulation, particularly of visceral fat, like increased insulin and/or leptin levels, reduced androgen levels, etc. (Gambineri et al., 2003) and therefore lead to and exacerbate obesity, metabolic syndrome, type 2 diabetes (T2D) (Bonsignore et al., 2013; Conde et al., 2014), and non-alcoholic fatty liver disease (NAFLD) (Jin et al., 2018).
Nevertheless, the cardiometabolic comorbidity burden is also high in nonobese OSA patients (Akahoshi et al., 2010; Gündüz et al., 2018), suggesting that other mechanisms apart from obesity contribute to the link OSA-dysmetabolism.
Using a variety of imaging techniques (computed tomography, magnetic resonance imaging, acoustic reflection, and cephalometric), several studies have also demonstrated the existence of small pharyngeal airway in patients with OSA, resulting from several syndromes or anatomical and skeletal structures alterations (Pillar and Shehadeh, 2008), which can be also a factor contributing to the link OSA-dysmetabolism. These anatomical alterations are always aggravated with increasing body fat and obesity (Pillar and Shehadeh, 2008).
Endocrine (de)Regulation in the Link OSA-Dysmetabolism
A growing body of epidemiological evidence supports an association between chronic sleep disorders and consequent chronic intermittent hypoxia, and the risk for obesity, insulin resistance, T2D, and many other endocrine-related diseases, showing a complex interaction between hormones and sleep disorders (González-Ortiz et al., 2000; Saaresranta and Polo, 2003; Pillar and Shehadeh, 2008) (Figure 1).
Figure 1
OSA may be a heterogeneous disorder in terms of its association with insulin resistance. On one hand, there are studies revealing a weak association between OSA and insulin resistance, but there are also several studies providing a strong association in favor of an independent association between OSA and insulin resistance. For example, Vgontzas et al. performed a study in which they included 14 obese men with sleep apnea and 11 BMI- and age-matched, obese non-apneic controls. The authors showed that mean fasting blood glucose levels were higher in the obese apneic compared to obese controls and that mean plasma insulin levels were also higher in those obese sleep apneic than in obese controls (Vgontzas et al., 2000). Subsequent studies showed that the association between OSA and insulin resistance was present even in nonobese subjects (Ip et al., 2002) or in mild forms of sleep apnea (Punjabi et al., 2002). This was confirmed by animal data: rats and mice submitted to CIH that mimicked OSA exhibited hyperinsulinemia and insulin resistance in the absence of obesity; pathological conditions not aggravated by the presence of increased weight (Olea et al., 2014; Shin et al., 2014; Sacramento et al., 2016; Martins et al., 2021). In addition, exhausting insulin secretion leading to beta-cell dysfunction and consequent hyperinsulinemia has been described in both animals and humans submitted to CIH or diagnosed with OSA, with special incidence in men (Polotsky et al., 2003; Pillar and Shehadeh, 2008; Wang et al., 2013). The fact that OSA is an independent risk factor for increased insulin resistance is also supported by the improvement in insulin sensitivity after 3 months of treatment with continuous positive airway pressure (CPAP) (Harsch et al., 2004; Pillar and Shehadeh, 2008). In fact, the most common treatment for moderate-severe OSA, the CPAP treatment, has been described to improve insulin sensitivity and decrease insulin levels in prediabetes (Weinstock et al., 2012; Pamidi et al., 2015) and T2D patients (Martinez-Ceron et al., 2016; Mokhlesi et al., 2016).
Another endocrine mediator that was shown to be altered in OSA is leptin. Leptin, an important adipokine secreted by the adipose tissue with known function as a satiety hormone, is a powerful respiratory stimulant (O'Donnell et al., 1999; Ribeiro et al., 2018). Leptin regulation is altered in OSA, with several studies reporting an increase in leptin levels in animal models of CIH (Polotsky et al., 2003; Olea et al., 2014) and in patients with OSA that correlated with elevated AHI (Phillips et al., 2000; Öztürk et al., 2003; Vgontzas et al., 2003; Ciftci et al., 2005; Pillar and Shehadeh, 2008), suggesting an adaptive compensatory mechanism to increase ventilation in OSA conditions. The relationship between hyperleptinemia and OSA and its metabolic comorbidities was further explored, with Polotsky et al. (2003) showing in leptin-deficient mice submitted to CIH that the increase in insulin resistance was dependent on the disruption of leptin pathways (Polotsky et al., 2003). In agreement, CPAP therapy reduced leptin levels, independently of BMI (Chin et al., 1999; Ip et al., 2000; Sanner et al., 2004; Pillar and Shehadeh, 2008). However, neither the effect of CIH on circulating leptin levels or even the levels of leptin in OSA patients nor the link between insulin resistance-OSA with the deregulation of leptin pathways was consensual. Some authors showed the absence of effect of CIH on leptin levels in animals (Briançon-Marjollet et al., 2016) and described that leptin levels of overweight subjects, children and adults, with and without OSA were not different (Yosunkaya et al., 2015; Van Eyck et al., 2017) which was consistent with the lack of effects of CPAP on leptin circulating levels (Yosunkaya et al., 2015). These differences in the role of leptin on cardiometabolic dysfunctions in OSA may indicate that leptin effects on OSA might depend on the severity and duration of the disease as well as with its interactions with obesity.
Ghrelin is another hormone that has been linked with OSA, being released by the gut, and often called the “hunger” hormone. Apart from regulating satiety and food intake, ghrelin also acts to modulate growth hormone secretion, gastric secretion and gastrointestinal motility, glucose metabolism and insulin secretion, cardiovascular functions, anti-inflammatory functions, reproductive functions, and bone formation (Gil-Campos et al., 2006). In a recent study of patients with OSA and BMI-matched control subjects, ghrelin levels were shown to be significantly higher in patients with OSA (Harsch et al., 2003; Pillar and Shehadeh, 2008). Also, Ursavas et al. (2010) described that ghrelin levels were increased in OSA patients correlating with AHI and with the Epworth sleepiness scale. Again, CPAP treatment of 2 days was sufficient to significantly reduce ghrelin levels in these patients (Harsch et al., 2003).
All this literature leads to the conclusion that disruptions in insulin, leptin, and/or ghrelin pathways contribute to metabolic dysfunction in OSA, also pointing toward possible effects of these hormones, due to their central effects, on the promotion of increased caloric intake and weight gain in patients with OSA. Also, a positive correlation between AHI and orexin levels, a central nervous system appetite regulator, may potentially explain the tendency toward weight gain in patients with OSA (Igarashi et al., 2003; Pillar and Shehadeh, 2008).
Another endocrine mechanism contributing to OSA-associated dysmetabolic states is the disruption of the hypothalamic-pituitary–adrenal (HPA) axis. It is known that repeated arousals can cause activation of the HPA axis leading to increased cortisol release (Späth-Schwalbe et al., 1998). Obesity acts as a HPA axis modulator by decreasing cortisol release, and the combination of both pathological situations can have a masking effect on the tone of this axis in OSA (Bratel et al., 1999; Vgontzas et al., 2007; Kritikou et al., 2016). However, Kritikou et al. showed that even in nonobese men or women with OSA there is an increase in cortisol levels, showing that the HPA axis-OSA association is independent of obesity. Looking at the available literature, there is controversy on the link of HPA axis and OSA since other studies fail to reveal this association (Grunstein et al., 1989; Nakamura et al., 2001; Barceló et al., 2008; Lam et al., 2009; Panaree et al., 2011) or showed a decrease in HPA activation in OSA patients (Karaca et al., 2013). The discrepancies between these studies can come from the fact that most have only assessed the involvement of the HPA axis in obese OSA patients, with a lack of data for nonobese OSA patients. In agreement with the activation of the HPA axis in OSA, CPAP had a significant effect on cortisol levels in both nonobese men and slightly obese women compared with the baseline despite CPAP not affecting the inflammation/metabolic profile of patients with OSA (Vgontzas et al., 2008; Kohler et al., 2009; Kritikou et al., 2014). Also, the administration of glucocorticoids leads to excessive cortisol levels, which then promote arousal and sleeplessness (Vgontzas and Chrousos, 2002). Likewise, patients with Cushing's syndrome, a pathological condition characterized by increased production of cortisol over a long period of time, have a high prevalence of OSA (Shipley et al., 1992). Cushing's patients complain of daytime fatigue and sleepiness resulting from the OSA condition and exacerbated by marked visceral obesity in those patients (Shipley et al., 1992; Vgontzas and Chrousos, 2002).
Inflammation and Oxidative Stress in OSA-Dysmetabolic States
Inflammation and oxidative stress caused by CIH/OSA might be other mechanisms contributing to dysmetabolic states in OSA. There is evidence that increased levels of cytokines in circulation are involved in physiological sleep regulation and that hypercytokinemia is present in OSA (Kapás et al., 1992; Opp et al., 1992). It is well known that a positive correlation between IL-6 or TNF α plasma levels, inflammatory cytokines, and the body mass index (BMI) occurs, and this should be further evidence for the link between OSA and visceral obesity since several studies also showed that IL-6, TNF α, leptin, and insulin levels were all elevated in sleep apnea and linked with visceral fat (Vgontzas et al., 2003).
Confirming the link between inflammation and dysmetabolism-OSA, Murphy et al. (2017) found that in OSA-insulin-resistant patients the AHI correlated significantly and independently with serum levels of sCD163, suggesting M1 macrophage polarization in OSA patients. These authors also suggested that CIH/OSA promotes insulin resistance through adipose tissue inflammation (Murphy et al., 2017). These effects were supported by the results obtained in mice where it was shown that prolonged exposure to intermittent hypoxia promotes visceral white adipose tissue inflammation (Gileles-Hillel et al., 2017). However, recent data obtained by Martins et al. (Martins et al., 2021) in rats submitted to mild CIH for 35 days and to severe CIH for 15 days, did not find any alterations in the expression of pro- and anti-inflammatory cytokines within the visceral adipose tissue, demonstrating that CIH induces early metabolic dysfunction independently of adipose tissue inflammation. Therefore, we could postulate that although adipose tissue inflammation might not be the trigger for metabolic dysfunction in OSA, it could appear lately with disease progression and contribute to the maintenance and worsening of dysmetabolic states (Figure 1).
Oxidative stress induced by CIH may also play a major role in the formation of reactive oxygen species (ROS) from leukocytes, the reduction in plasma levels of nitrite, nitrate, and antioxidant capacity, increased lipid peroxidation, and increased predisposition to atherogenesis (Ramar and Caples, 2011; Bromińska et al., 2017) contributing therefore to dysmetabolic states. In fact, it is described that CIH in rats induces a whole-body oxidative status manifested by an increase in lipid peroxides and diminished superoxide dismutase (SOD) activities (Olea et al., 2014). Pointing toward a contribution of visceral adipose tissue oxidative stress to dysmetabolism in OSA, Gileles-Hillel et al. (2017) found that metabolic dysfunction after long periods of exposure to CIH is associated with increased ROS production and alterations in the electron transport chain in visceral adipose tissue (Gileles-Hillel et al., 2017). However, short exposure to mild or severe CIH during short periods did not change visceral adipose tissue oxidative stress in rats (Martins et al., 2021) suggesting that oxidative stress in the adipose tissue may develop with disease progression (Figure 1), not being involved in the triggering of metabolic dysfunction in OSA (Almendros et al., 2011; Lavie, 2015; Ferreira et al., 2020).
Sympathetic Activation in OSA-Cardiometabolic Associated Pathologies
Sympathetic nervous system activation has been also postulated as a mechanism responsible for OSA-associated cardiometabolic comorbidities (Figure 1). OSA-associated CIH and concomitant privation of available O2 and increase in arterial CO2 results in sympathetic activation and consequent catecholamine secretion (Somers and Abboud, 1988), mechanisms that have been postulated to also be in the basis of OSA associated-cardiometabolic comorbidities, such as hypertension (Levinson and Millman, 1991; Carlson et al., 1993; Somers et al., 1995; Prabhakar and Kumar, 2010). It has been described that muscle sympathetic activity and blood and urine catecholamine levels are higher in sleep apneic patients in comparison to age- and BMI-matched controls (both norepinephrine and epinephrine) (Narkiewicz and Somers, 1999; Dempsey et al., 2010). Additionally, several studies show that chronic intermittent hypoxia can induce hypertension and sympathetic activation, both in laboratory animals (Fletcher et al., 1992; Greenberg et al., 1999; Zoccal et al., 2008; Marcus et al., 2010; Aller et al., 2020; Ferreira et al., 2020; Correia et al., 2021) and in humans (Tamisier et al., 2011). However, since sleep interruption and arousals, characteristic of the OSA condition, can also cause hypertension, some studies suggest that recurrent sleep disturbance also contributes to sympathetic overactivity and catecholamines levels increase in OSA patients, remaining to understand the specific impact of each parameter (Faraut et al., 2012; Chouchou et al., 2013; Taylor et al., 2016) on arterial pressure.
Increased Carotid Body Chemosensitivity
The carotid bodies (CBs) are peripheral arterial chemoreceptors located at the bifurcation of the common carotid artery that classically sense and respond to changes in arterial blood O2, CO2, and pH levels. Apart from their role in the control of ventilation, it is consensual that the CBs are metabolic sensors involved in energy homeostasis (Conde et al., 2017; Conde and Guarino, 2018; Sacramento et al., 2020). CB activity is integrated in the brain via the CB sensory nerve, the carotid sinus nerve (CSN). Central integration of CB activity is aimed, primarily, to normalize the altered blood gases via hyperventilation (Gonzalez et al., 1994) and to regulate blood pressure, cardiac performance, and metabolism via sympathetic nervous system activation (Conde et al., 2017; Conde and Guarino, 2018). While it is quite well described that CB overactivation is responsible for the increase in sympathetic activity and blood pressure in CIH/OSA (Fletcher et al., 1992; Narkiewicz and Somers, 1999; Peng et al., 2003, 2009; Rey et al., 2004; Prabhakar et al., 2005) (Figure 1), the idea that the CBs might mediate the link between OSA and dysmetabolism emerged more recently. This idea was first supported by a study in mice submitted to CIH in where CSN denervation prevented the development of CIH-induced fasting hyperglycemia and hepatic glucose output (Shin et al., 2014). Supporting this link between the CB, dysmetabolism, and OSA, several studies demonstrated that the CB has a key role in the control of peripheral insulin sensitivity and glucose homeostasis since: (1) CSN resection prevents and reverses insulin resistance, glucose intolerance and dyslipidemia, which are pathological dysmetabolic characteristics, in hypercaloric diet rats (Ribeiro et al., 2013; Sacramento et al., 2017, 2018); (2) CSN resection prevents and normalizes the overactivation of the sympathetic nervous system associated with the intake of hypercaloric diets in rats (Ribeiro et al., 2013; Sacramento et al., 2017; Cracchiolo et al., 2019); and (3) CB activity is increased in animal models of metabolic syndrome and diabetes (Ribeiro et al., 2013; Dos Santos et al., 2018; Cracchiolo et al., 2019) and in prediabetic patients (Cunha-Guimaraes et al., 2020). Also in agreement with the role of the CB as a metabolic sensor whose dysfunction is associated with dysmetabolic states, several data showed that CB activity is modulated by hormones such as insulin (Ribeiro et al., 2013; Cracchiolo et al., 2019) and leptin (Ribeiro et al., 2018; Caballero-Eraso et al., 2019), and also by inflammation [for a review see (Conde et al., 2020)] whose levels are known to be deregulated in OSA (Ryan et al., 2005; Da Rosa et al., 2012). So, it could be postulated that CIH, by acting directly on the CB or indirectly by altering insulin secretion from the pancreas or by increasing leptin production in the adipose tissue and inflammation, leads to an increase in CB chemosensitivity promoting dysmetabolism (Figure 2).
Figure 2
All together we can conclude that multiple mechanisms contribute to the link between OSA and metabolic dysfunction. Additionally, we also conclude that several of these mechanisms are interrelated with each other as for example the increased CB chemosensitivity and the increased sympathetic activation in OSA. Moreover, we can also postulate that the different mechanisms may contribute differently to the link OSA-dysmetabolism depending on disease state and progression.
Gender Differences in OSA-Dysmetabolism Link
In the context of the previous discussion about the mechanisms involved in the link OSA-dysmetabolism and knowing that OSA disease settlement and progression are different in men and women (Table 1), sex-specific hormones and gender differences in the OSA-dysmetabolism link are summarized in Figure 3, and will be discussed in this section.
Figure 3
In this scenario, we will discuss the most important sex hormones including androgens (e.g., testosterone), estrogens (e.g., 17β-estradiol), and progesterone, which are steroid hormones all derived from cholesterol (Stoffel-Wagner, 2001), by describing its general mechanisms of action as well as their specific actions in the context of OSA and dysmetabolic conditions.
Typically, these hormones can affect gene expression by binding to classical nuclear receptors, binding to steroid receptors located on cell membranes, acting on ion-gated membrane receptors, or modulating neurotransmitter receptor function (Behan and Wenninger, 2008). Estrogen exerts its effects by genomic or non-genomic mechanisms, differing in the latencies of each mechanism by minutes to hours for the former, and seconds to minutes for the latter (Brailoiu et al., 2007). In the genomic mechanism, estrogen binds to its receptor and translocates to the nucleus with a subsequent regulation of target genes (Nilsson et al., 2001). In the non-genomic mechanism, estrogen acts at the plasma membrane, activating signal transduction pathways and promoting calcium influx (Vasudevan and Pfaff, 2008). Progesterone also exerts its effect by classical genomic mechanisms and non-genomic effects of progesterone metabolites include allosteric modulation of the GABAA receptor in the brain (Smith et al., 2007). Androgen receptors are also members of the nuclear receptor superfamily and can also exert rapid, non-genomic effects via membrane receptors (Michels and Hoppe, 2008) (Michels and Hoppe, 2008).
Estrogen, progesterone, and testosterone are present in both women and men with different levels between gender and during their lifetime. Testosterone circulating levels are typically higher in men than in women reaching their peak at 18–40 years old in male humans (Smith et al., 1992; Bhasin et al., 2006). Serum estrogens levels are low and similar between genders at birth and higher in women in adult life (Amateau et al., 2004).
Sex Hormones and OSA
Sleep patterns differ between men and women, with women reporting sleeping longer, but with more disturbed sleep and waking up more times than men (Figure 3) (Orff et al., 2014). Hormonal changes associated with gender-specific hormonal composition, the menstrual cycle, pregnancy, postpartum, oral contraceptive use, psychological disturbances (depression, anxiety, etc.), and/or lifestyle are on the basis of male vs. female differences and specific OSA-dysmetabolism relationship in women (Krystal et al., 1998; Krystal, 2003).
Some controversy can be found when the question of which sex hormone is the most effective in the regulation of breathing rises. In fact, for many years, hyperventilation in human pregnancy in the luteal phase of the menstrual cycle has been associated with elevated progesterone levels (Behan and Wenninger, 2008). What is known is that during the menstrual cycle, female sex hormones affect respiratory control and upper airway stability, and these hormones are described to be protective and responsible for the lower rates of OSA in women in comparison to men (Figure 3) (Netzer et al., 2003). In fact, women diagnosed with OSA have lower levels of progesterone, estradiol, and 17-OH progesterone (Netzer et al., 2003). Also, previous polysomnographic studies showed that the prevalence and severity of OSA are increased in postmenopausal vs. premenopausal women independently of body weight (Dancey et al., 2001). Progesterone is an important breath stimulant hormone therefore it has been suggested that the decrease in progesterone levels in menopause must be involved in the increase in OSA prevalence in the postmenopausal period (Figure 3) (Orff et al., 2014). Nonetheless, administration of synthetic progestin to healthy men increased minute ventilation as well as the hypoxic and hypercapnic ventilatory responses (Skatrud et al., 1978). Thus, it is clear that progesterone stimulates breathing in both men and women but the exact mechanism is unknown with some studies arguing that respiratory effects of progesterone are mediated by progesterone receptors-containing cells in the hypothalamus, by modulating the release of neuromodulators such as serotonin and/or binding and modulating GABA receptors function (Behan and Wenninger, 2008). Moreover, Boukari et al. (2016) showed that administration of siRNA against membrane progesterone receptor-β, but not -α, in dorsal brainstem increased apnea frequency, suppressed the response to hypoxia in male and female mice, and reduced by ~50% the response to hypercapnia in male and female mice (Boukari et al., 2016). Additionally, the authors showed that females exhibited a higher ventilatory response to hypoxia and hypercapnia than males, effects abolished by membrane progesterone receptor-β siRNA, but not -α, demonstrating that membrane progesterone receptor-β in the dorsal brainstem establishes sex-specific chemoreflex responses and reduces apnea frequency in adult mice (Boukari et al., 2016). Another mechanism by which sex hormones can act to modulate breathing and increase the response to hypoxia is by acting on the CB (Figure 2) (Joseph et al., 2013). It was shown that when ventilation—basal and in response to hypoxia—and CB neural output were evaluated in castrated male cats before and after 1 week of a placebo, estrogen, progesterone, or estrogen plus progesterone treatment, animals receiving progesterone alone or in combination with estradiol had higher ventilation and CB neural output responsiveness than animals receiving placebo or estrogen (Hannhart et al., 1990). However, the slope of the correlation between ventilation and CB neural output was higher in estrogen-treated than in the placebo animals, suggesting a combined action of estrogen and progesterone in central and CB sites, respectively, to modulate breathing (Hannhart et al., 1990). In agreement, progesterone also increased CB response to hypoxia in rats and mice (Joseph et al., 2006, 2013), effects consistent with the presence of progesterone receptors in the CB (Joseph et al., 2006, 2013). The CB-mediated effects of progesterone on ventilation were confirmed in newborn animals since the CB responses to hypoxia and nicotine were dramatically decraesed by mifepristone, a progesterone and glucocorticoid receptor antagonist with weak anti-androgenic activity (Joseph et al., 2012).
More recently, the effect of progesterone on arterial blood pressure, respiratory chemoreflexes, and oxidative stress in the central nervous system was studied in ovariectomized female rats submitted to room air and to 1 week of CIH (7 days, 10% O2, 10 cycles h-1, 8 h day-1) (Joseph et al., 2020). The authors found that while progesterone administration does not prevent hypertension elicited by CIH, it normalizes respiratory control, and reduces cerebral oxidative stress, suggesting that modulation of progesterone levels can attenuate the consequences of sleep apnea in menopausal women. Although it remains to be established if these effects of progesterone on CIH female rats could be mediated by the CB or other central structures.
Regarding the effect of estrogen on ventilation little is known but it has been implicated in the control of breathing since it has been associated with OSA and estrogen or combined estrogen-progesterone therapy have therapeutic effects over ventilation regulation (Shahar et al., 2003). In fact, as stated before and described by Hannhart et al. (1990) while estradiol did not change ventilation and CB neural output in cats, the correlation between ventilation and CB neural output was higher in estrogen-treated than in the placebo animals, suggesting an interaction between progesterone and estradiol in breathing control.
Finally, testosterone is implicated in OSA and breathing control due to the high OSA prevalence and low levels of testosterone in middle-aged men (Young et al., 2003) and also due to the fact that testosterone administration in women promoted increase in ventilation during wakefulness and increased ventilatory sensitivity to CO2 during sleep (Ahuja et al., 2007). These hormones have synergistic effects over ventilation since for example administration of testosterone in healthy men and women can upregulate progesterone receptors in the brain and therefore increase minute ventilation and hypoxic responses (Simpson et al., 2002). From the major structures involved in the control of breathing, we must highlight the CB and the brainstem due to the presence of sex hormones receptors on these sites and alteration of the activity of these structures when changes in hormones levels occur (Behan and Wenninger, 2008).
Sex Hormones and OSA-Dysmetabolism Link
Dysmetabolic states prevalence differs between genders, not only on the higher prevalence of obesity in men, especially visceral obesity, but also in the prevalence of other pathological states as insulin resistance, T2D, etc. (Goodpaster et al., 2003; Gautier et al., 2013). The impact of visceral obesity on OSA incidence and severity can also explain the higher prevalence of OSA in men, the gender that is more affected by the deposition of fat in the abdominal sites (Figure 3) (Gautier et al., 2013). However, women with OSA exhibit stronger correlations than men between OSA and diabetes, hypertension, age, BMI, and waist-to-hip ratio, with men demonstrating a slightly stronger association with metabolic syndrome (Fietze et al., 2019). These stronger correlations in women than men for OSA and hypertension have been found by other authors, although with no gender differences regarding BMI, snoring, and diabetes (Huang et al., 2018).
Reduced testosterone levels represent an independent cardiovascular risk factor in the general male population and are intimately correlated with obesity, insulin resistance, and visceral fat deposition (Mårin et al., 1992; Mårin, 1998). Testosterone and other androgens stimulate lipolysis in the adipose tissue by inhibiting lipoprotein lipase activity, particularly at the visceral level (Björntorp, 1996; Gambineri and Pasquali, 2000). In fact, men with low levels of testosterone present enlarged visceral fat that can be completely reversed with testosterone hormone replacement (Gambineri and Pasquali, 2000). The sex-specific difference of the impact of OSA on glucose metabolism remains mostly unexplored.
Interestingly, increased oxidative stress, low testosterone, and male sexual dysfunction are shared outcomes between middle-aged rats and CIH exposed young male rats, these results suggesting that CIH-induced oxidative stress is one of the primary factors involved in CIH-induced reproductive aging in males.
Another factor that can explain the low levels of OSA and its link with cardiometabolic comorbidities in pre-menopause women and the increase in their prevalence post-menopause is the effect of sex hormones, particularly progesterone at the CB (see Section Sex Hormones and OSA). Progesterone and estradiol receptors are present in the CB and the activation of progesterone receptors within the CB was shown to decrease CB response to hypoxia in animals—mouse, rat, and cat (Hannhart et al., 1990; Joseph et al., 2006, 2013). In agreement with the effect of sex hormones on ventilation and on CB, the reduction of ovarian hormones, either by ovariectomy or aging, attenuates the ventilatory response to hypoxia (Fournier et al., 2015). Knowing that OSA associated cardiometabolic pathologies run with altered CB activity (Conde et al., 2014; Iturriaga, 2018) and knowing the impact of these hormones on the differences in the prevalence of OSA, we might speculate that progesterone/estradiol on the CB must have a role on the gender-specific OSA-dysmetabolism link.
Also, loss of estrogens after menopause are associated with obesity, cardiovascular diseases, and the increase in inflammatory markers, giving to menopausal women a similar prevalence of sleep apnea as in men (Vgontzas and Chrousos, 2002). The lower OSA prevalence in women seems to be also associated with an inflammatory profile less severe in women than in men, although women suffering from OSA are more obese than men (Figure 3) (Bonsignore et al., 2012). The stronger elevation of inflammatory markers in men than in womenis consistent with the greater degree of sleepiness observed in men.
Women with polycystic ovary syndrome (PCOS), a condition associated with hyperandrogenism and insulin resistance, have increased sleep-disordered breathing and daytime sleepiness than controls, supporting again the impact of insulin resistance in OSA pathology (Dunaif, 1997). Given that PCOS is associated with insulin resistance and central obesity, these data reinforce the hypothesis that obesity and/or insulin resistance is at the basis of the pathologic mechanisms leading to OSA in women (Van Cauter and Spiegel, 1997).
Therapies on Metabolic Control and OSA
In this section a detailed discussion about the therapeutics for control of OSA can be found as well as their impact of those same applications over metabolic control with special attention to CPAP, hormone replacement therapy (HRT) and other physical and nutritional interventions.
CPAP Treatment for OSA and Dysmetabolism
The most widely used therapy for OSA treatment is CPAP. The beneficial effects of CPAP appear to be partial as previous studies have shown that CPAP does not, in short-term use, affect the inflammation, insulin resistance, or metabolic profile of patients with sleep apnea (Saini et al., 1993; Smurra et al., 2001). However, in long-term and high adherence CPAP treatment, beneficial effects on insulin levels and glucose tolerance have been shown by some authors (Brooks et al., 1994). This is important given the independent association of insulin resistance and inflammation with cardiovascular morbidity and mortality (Kritikou et al., 2016). In a previous meta-analysis, CPAP significantly improved insulin resistance in non-diabetic patients with moderate to severe OSA, without significant changes in BMI or fasting blood glucose (Yang et al., 2013). Another study demonstrated a significant increase in insulin secretion and decrease in circulating leptin, total cholesterol, and LDL cholesterol by CPAP treatment, showing the protective effects of CPAP treatment against the development of metabolic syndrome in OSA patients (Çuhadaroglu et al., 2009). Similar to OSA prevalence, gender impacts also on CPAP effectiveness since the requirements for this therapy are higher for men than women for the same OSA severity (Yukawa et al., 2009; Jayaraman et al., 2011).
HRT and Its Impact on OSA and Metabolic Dysfunction
The positive effects of HRT on OSA and/or metabolic dysfunction raises some concerns since there is controversy surrounding the studies found in the literature. In fact, it has been assumed that the beneficial or adverse effects of HRT will depend on the patient's comorbidities, hormone type or combination of hormones, route of administration, and dosage (Fineberg, 2000). For example, the impact of HRT on promoting an increase in the levels of triglycerides, based on the administration of conjugated estrogens, can be avoided using transdermal estrogen or oral estradiol (Fineberg, 2000). Also, few long-term risks for the development of diabetes mellitus have been shown for women receiving postmenopausal HRT (Mauvais-Jarvis et al., 2017). In fact, large controlled trials suggested that HRT using estrogens in menopausal women reduces the incidence of type 2 diabetes (Espeland et al., 1998; Kanaya et al., 2003; Margolis et al., 2004; Salpeter et al., 2006; Manson et al., 2013). These and many other studies have demonstrated that HRT can have beneficial effects on body weight, insulin sensitivity, carbohydrate or lipid metabolism (Mauvais-Jarvis et al., 2017). In one study combined HRT treatment prevented, for example, an increase in abdominal fat in menopausal women, which is associated with insulin resistance and type 2 diabetes mellitus (Haarbo et al., 1991). However, in another study the changes in body composition associated with menopause, with gain in fat mass and loss in lean mass, were not prevented by HRT combining estrogen, progesterone, and calcium (Aloi et al., 1995). Nevertheless, women in the postmenopausal state, undergoing HRT combining both estrogens and progesterone, have a similar prevalence of OSA when compared with premenopausal women, and a lower prevelance than in postmenopausal women without HRT (Shahar et al., 2003). Furthermore, it was shown that the exogenous application of progesterone in rats reduced the frequency of apneas recorded during sleep, an effect abolished by mifepristone, a progesterone and glucocorticoid receptor antagonist (Yamazaki et al., 2005). These effects agree with the lower levels of sex hormones—progesterone, estradiol, and 17-OH progesterone—in women with sleep apnea (Netzer et al., 2003) and with the effects of HRT in OSA in post-menopausal women and suggest that HRT might have a significant role in the prevention or treatment of OSA in women. Also, in men testosterone levels tend to significantly increase after weight loss, and this could play a role in favoring weight maintenance in men (Pasquali et al., 1988). In fact, testosterone supplementation in both hypogonadal and obese men has been found to selectively reduce visceral fat and improve lipid abnormalities and insulin sensitivity at the same time that it improves OSA-related dysfunctions (Gambineri and Pasquali, 2000).
Regarding insulin sensitivity impact, a lot of controversy is also present in the literature mainly due to the routes of administration of hormones since orally administered HRT is subject to first-pass hepatic metabolism, unlike the transdermal route of administration. Also, the different methods used to assess antidiabetic actions of HRT can justify the discrepancies in the results described for the use of this type of therapy. For example, oral estrogen replacement consisting of 2 mg of oral estradiol plus 1 mg/day of norethisterone decreased blood glucose, c-peptide, total cholesterol, and low-density lipoprotein showing a clear improvement in insulin action and carbohydrate homeostasis (Anderson et al., 1997). Yet, another study using transdermal estradiol treatment in comparison to oral conjugated estrogens showed that transdermal HRT did not alter insulin sensitivity or glucose tolerance but oral administration resulted in a deterioration of glucose metabolism (Godsland et al., 1993).
Some of the adverse effects of HRT on carbohydrate metabolism and insulin sensitivity have resulted from the use of higher doses of estrogens and the use of progestogens with higher androgenic effects. Progestogen-alone formulations containing levonorgestrel and medroxyprogesterone are associated with deterioration of glucose tolerance, whereas norethisterone has little effect. Also, the use of estradiol and dydrogesterone in oral formulations seems to avoid undesirable effects on the lipid metabolism (Foster and Balfour, 1997).
The mechanisms involved in the impact of HRT over metabolism in the context of OSA are not well understood and more research is needed. From the ones already detected we can find the impact of HRT in decreasing visceral fat deposition by increasing lipid oxidation and enhancing energy expenditure (Kim et al., 2014), in improving glucose homeostasis, and insulin sensitivity by the direct action of estrogens in estrogen receptors in the liver, skeletal muscle, adipose tissue or pancreatic cells (Tiano and Mauvais-Jarvis, 2012; Mauvais-Jarvis, 2016), or by preventing the increase in fasting glucose and insulin levels due to the impact on hepatic glucose production and hepatic insulin clearance (Kim et al., 2014).
Overall, since the beginning of HRT application in clinical practice, different and contrary opinions have been raised in the literature, but nowadays the general opinion of the scientific and medical communities is that HRT should be used with the smallest hormone dose possible and taking into account the comorbidities of each patient.
Other Therapies With Impact Over OSA and Dysmetabolism
Besides CPAP and HRT, there are other therapies for OSA, comprising mandibular repositioning splints (MRS) and therapies with low application in clinical practice such as hypoglossal nerve stimulation and surgery. These therapies have been assessed in both women and men, although the literature lacks studies involving the female population (Garg et al., 2016; Wray and Thaler, 2016). However, two studies have suggested that MRS use is more efficient in women compared to men (Marklund et al., 2004; Vecchierini et al., 2019). In fact, obese men or men that gain weight during MRS treatment exhibit a reduced efficacy of their treatment with this device, and were often followed up with other OSA treatments like CPAP.
Nutritional and behavioral treatments to achieve weight loss have also been seen as beneficial in improving respiratory function (Pasquali et al., 1988) and metabolic abnormalities (Muscelli et al., 1997) with a higher extent for men than women (Newman et al., 2005).
Conclusion
While there are clear sex differences in the pathological mechanisms, symptoms presentation, and disease manifestation in the link between OSA and dysmetabolism, more information needs to be unveiled to better understand sex-related phenotypes in OSA as well as to develop diagnostic tools for OSA in women.
Funding
The author FM is funded by the Portuguese Foundation for Science and Technology with contract reference CEECIND/04266/2017.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.
Author contributions
FM and SC wrote or contributed to the writing of the manuscript. The authors have approved the final version of the manuscript, and all persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AhujaD.MateikaJ. H.DiamondM. P.BadrM. S. (2007). Ventilatory sensitivity to carbon dioxide before and after episodic hypoxia in women treated with testosterone. J. Appl. Physiol.102, 1832–1838. 10.1152/japplphysiol.01178.2006
2
AkahoshiT.UematsuA.AkashibaT.NagaokaK.KiyofujiK.KawaharaS.et al. (2010). Obstructive sleep apnoea is associated with risk factors comprising the metabolic syndrome. Respirology15, 1122–1126. 10.1111/j.1440-1843.2010.01818.x
3
AllerR.SigüenzaR.PinaM.LasernaC.AntolínB.BurgueñoB.et al. (2020). Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor. Endocrine.20:2268. 10.1007/s12020-020-02268-7
4
AlmendrosI.FarréR.PlanasA. M.TorresM.BonsignoreM. R.NavajasD.et al. (2011). Tissue oxygenation in brain, muscle, and fat in a rat model of sleep apnea: Differential effect of obstructive apneas and intermittent hypoxia. Sleep34, 1127–1133. 10.5665/SLEEP.1176
5
AloiJ. F.VaswaniA.RussoL.SheehanM.FlasterE. (1995). The influence of menopause and hormonal replacement therapyon body cell mass and body fat mass. Am. J. Obstetr. Gynecol.172, 896–900. 10.1016/0002-9378(95)90018-7
6
AmateauS. K.AltJ. J.StampsC. L.McCarthyM. M. (2004). Brain estradiol content in newborn rats: Sex differences, regional heterogeneity, and possible de novo synthesis by the female telencephalon. Endocrinology145, 2906–2917. 10.1210/en.2003-1363
7
AndersonB.MattssonL.HahnL.MarinP.LapidusL.HolmG.et al. (1997). Hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with. J. Clinic. Endocrinol. Metabol.82, 638–643. 10.1210/jcem.82.2.3746
8
BarcelóA.BarbéF.De La PeñaM.MartinezP.SorianoJ. B.PiérolaJ.et al. (2008). Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax63, 946–950. 10.1136/thx.2007.093740
9
BehanM.WenningerJ. M. (2008). Sex steroidal hormones and respiratory control. Respirat. Physiol. Neurobiol.164, 213–221. 10.1016/j.resp.2008.06.006
10
BhasinS.CunninghamG. R.HayesF. J.MatsumotoA. M.SnyderP. J.SwerdloffR. S.et al. (2006). Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clinic. Endocrinol. Metabol.91, 1995–2010. 10.1210/jc.2005-2847
11
BjörntorpP.. (1996). The regulation of adipose tissue distribution in humans. Int. J. Obes. Relat. Metab. Disord.20, 291–302.
12
BonsignoreM. R.McNicholasW. T.MontserratJ. M.EckelJ. (2012). Adipose tissue in obesity and obstructive sleep apnoea. Euro. Respirat. J.39, 746–767. 10.1183/09031936.00047010
13
BonsignoreM. R.SaaresrantaT.RihaR. L. (2019). Sex differences in obstructive sleep apnoea. Euro. Respirat. Rev.28, 1–11. 10.1183/16000617.0030-2019
14
BonsignoreT.BorelA. L.MachanE.GrunsteinR. (2013). Sleep apnoea and metabolic dysfunction. Euro. Respirat. Rev.22, 353–364. 10.1183/09059180.00003413
15
BoukariR.RossignolO.BaldyC.MarcouillerF.BairamA.JosephV. (2016). Membrane progesterone receptor-, but not-, in dorsal brain stem establishes sex-specific chemoreflex responses and reduces apnea frequency in adult mice. J. Appl. Physiol.121, 781–791. 10.1152/japplphysiol.00397.2016
16
BrailoiuE.DunS. L.BrailoiuG. C.MizuoK.SklarL. A.OpreaT. I.et al. (2007). Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J. Endocrinol.193, 311–321. 10.1677/JOE-07-0017
17
BratelT.WennlundA.CarlströmK. (1999). Pituitary reactivity, androgens and catecholamines in obstructive sleep apnoea. Effects of continuous positive airway pressure treatment (CPAP). Respirat. Med.93, 1–7. 10.1016/S0954-6111(99)90068-9
18
Briançon-MarjolletA.MonneretD.HenriM.Joyeux-FaureM.TotosonP.CachotS.et al. (2016). Intermittent hypoxia in obese Zucker rats: cardiometabolic and inflammatory effects. Experiment. Physiol.101, 1432–1442. 10.1113/EP085783
19
BromińskaB.RuchałaM.Cyrańska-ChyrekE.Kuznar-KamińskaB.KostrzewskaM.Batura-GabryelH. (2017). State of the art paper Obstructive sleep apnea and hormones—a novel insight. Arch. Med. Sci.13, 875–884. 10.5114/aoms.2016.61499
20
BrooksB.CistulliP. A.BorkmanM.RossG.McGheeS.GrunsteinR. R.et al. (1994). Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: Effect of continuous positive airway pressure treatment on insulin responsiveness. J. Clinic. Endocrinol. Metabol.79, 1681–1685. 10.1210/jcem.79.6.7989475
21
Caballero-ErasoC.ShinM. K.PhoH.KimL. J.PichardL. E.WuZ. J.et al. (2019). Leptin acts in the carotid bodies to increase minute ventilation during wakefulness and sleep and augment the hypoxic ventilatory response. J. Physiol.597, 151–172. 10.1113/JP276900
22
CarlsonJ. T.HednerJ.ElamM.EjnellH.SellgrenJ.WallinB. G. (1993). Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest103, 1763–1768. 10.1378/chest.103.6.1763
23
ChinK.ShimizuK.NakamuraT.NaraiN.MasuzakiH.OgawaY.et al. (1999). Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation100, 706–712. 10.1161/01.CIR.100.7.706
24
ChouchouF.PichotV.PépinJ. L.TamisierR.CelleS.MaudouxD.et al. (2013). Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: The PROOF-SYNAPSE study. Euro. Heart J.34, 2122–2131. 10.1093/eurheartj/eht208
25
CiftciT. U.KokturkO.BukanN.BilgihanA. (2005). Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration72, 395–401. 10.1159/000086254
26
CondeJ. F.GuarinoM. P. (2018). Carotid body: a metabolic sensor implicated in insulin resistance. Physiol. Genom.50, 208–214. 10.1152/physiolgenomics.00121.2017
27
CondeS. V.SacramentoJ. F.GuarinoM. P.GonzalezC.ObesoA.DiogoL. N.et al. (2014). Carotid body, insulin and metabolic diseases: Unravelling the links. Front. Physiol.5:418. 10.3389/fphys.2014.00418
28
CondeT.MartinsJ. F.MartinsF. O. (2020). Immunity and the carotid body: implications for metabolic diseases. Bioelectron. Med.6:5. 10.1186/s42234-020-00061-5
29
CondeT.MonteiroE. C.SacramentoJ. F. (2017). Purines and carotid body: new roles in pathological conditions. Front. Pharmacol.17:913. 10.3389/fphar.2017.00913
30
CorreiaM. J.PimpãoA. B.Lopes-CoelhoF.SequeiraC. O.CoelhoN. R.Gonçalves-DiasC.et al. (2021). Aryl hydrocarbon receptor and cysteine redox dynamics underlie (Mal)adaptive mechanisms to chronic intermittent hypoxia in kidney cortex. Antioxidants10:1484. 10.3390/antiox10091484
31
CracchioloM.SacramentoJ. F.MazzoniA.PanareseA.CarpanetoJ.CondeS.et al. (2019). Decoding neural metabolic markers from the carotid sinus nerve in a type 2 diabetes model. IEEE Trans. Neural Syst. Rehabil. Eng.27, 2034–2043. 10.1109/TNSRE.2019.2942398
32
ÇuhadarogluÇ.UtkusavaşA.ÖztürkL.SalmanS.EceT. (2009). Effects of nasal CPAP treatment on insulin resistance, lipid profile, and plasma leptin in sleep apnea. Lung187, 75–81. 10.1007/s00408-008-9131-5
33
Cunha-GuimaraesJ. P.GuarinoM. P.TimóteoA. T.CairesI.SacramentoJ. F.RibeiroM. J.et al. (2020). Carotid body chemosensitivity: early biomarker of dysmetabolism in humans. Eur. J. Endocrinol.182, 549–557. 10.1530/EJE-19-0976
34
Da RosaD. P.ForgiariniL. F.BaronioD.Feij,óC. A.MartinezD.MarroniN. P. (2012). Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver. Mediat. Inflamm.2012:79419. 10.1155/2012/879419
35
DanceyD. R.HanlyP. J.SoongC.LeeB.HoffsteinV. (2001). Impact of menopause on the prevalence and severity of sleep apnea. Chest120, 151–155. 10.1378/chest.120.1.151
36
DempseyJ. A.VeaseyS. C.MorganB. J.O'DonnellC. P. (2010). Pathophysiology of sleep apnea. Physiol. Rev.90, 47–112. 10.1152/physrev.00043.2008
37
Dos SantosE.SacramentoJ. F.MeloB. F.CondeS. V. (2018). Carotid Body Dysfunction in diet-induced insulin resistance is associated with alterations in its morphology. Adv. Experiment. Med. Biol.1071, 103–108. 10.1007/978-3-319-91137-3_13
38
DunaifA.. (1997). Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Rev.18, 774–800. 10.1210/er.18.6.774
39
EspelandM. A.MarcovinaS. M.MillerV.WoodP. D.WasilauskasC.SherwinR.et al. (1998). Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation97, 979–986. 10.1161/01.CIR.97.10.979
40
FarautB.TouchetteÉ.GambleH.Royant-ParolaS.SafarM. E.VarsatB.et al. (2012). Short sleep duration and increased risk of hypertension: A Primary care medicine investigation. J. Hypertens.30, 1354–1363. 10.1097/HJH.0b013e32835465e5
41
FerreiraC. B.SchoorlemmerG. H.RochaA. A.CravoS. L. (2020). Increased sympathetic responses induced by chronic obstructive sleep apnea are caused by sleep fragmentation. J. Appl. Physiol.129, 163–172. 10.1152/japplphysiol.00811.2019
42
FietzeI.LaharnarN.ObstA.EwertR.FelixS. B.GarciaC.et al. (2019). Prevalence and association analysis of obstructive sleep apnea with gender and age differences—Results of SHIP-Trend. J. Sleep Res.28, 1–9. 10.1111/jsr.12770
43
FinebergS. E.. (2000). Glycaemic control and hormone replacement therapy: implications of the postmenopausal estrogen/progestogen intervention (PEPI) Study. Drugs Aging17, 453–461. 10.2165/00002512-200017060-00003
44
FletcherE. C.LesskeJ.BehmR.MillerC. C.StaussH.UngerT. (1992). Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J. Appl. Physiol.72, 1978–1984. 10.1152/jappl.1992.72.5.1978
45
FosterR. H.BalfourJ. A. (1997). Estradiol and dydrogesterone. Drugs Aging11, 309–332. 10.2165/00002512-199711040-00006
46
FournierS.GulemetovaR.BaldyC.JosephV. (2015). Neonatal stress affects the aging trajectory of female rats on the endocrine, temperature, and ventilatory responses to hypoxia. Am. J. Physiol. Regulat. Integrat. Comparat. Physiol.308, R659–R667. 10.1152/ajpregu.00418.2014
47
FranklinK. A.SahlinC.StenlundH.LindbergE. (2013). Sleep apnoea is a common occurrence in females. Euro. Respirat. J.41, 610–615. 10.1183/09031936.00212711
48
GambineriA.PasqualiR. (2000). Testosterone therapy in men: clinical and pharmacological perspectives. J. Endocrinol. Investigat.23, 196–214. 10.1007/BF03343707
49
GambineriA.PelusiC.PasqualiR. (2003). Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J. Endocrinol. Investigat.26, 493–498. 10.1007/BF03345209
50
GargR. K.AfifiA. M.SanchezR.KingT. W. (2016). Obstructive sleep apnea in adults: the role of upper airway and facial skeletal surgery. Plastic Reconstruct. Surg.138, 889–898. 10.1097/PRS.0000000000002481
51
GautierA.BonnetF.DuboisS.MassartC.GroshenyC.BachelotA.et al. (2013). Associations between visceral adipose tissue, inflammation and sex steroid concentrations in men. Clinical Endocrinol.78, 373–378. 10.1111/j.1365-2265.2012.04401.x
52
Gil-CamposM.AguileraC. M.CañeteR.GilA. (2006). Ghrelin: a hormone regulating food intake and energy homeostasis. Br. J. Nutri.96, 201–226. 10.1079/BJN20061787
53
Gileles-HillelA.AlmendrosI.KhalyfaA.NigdeliogluR.QiaoZ.HamanakaR. B.et al. (2017). Prolonged exposures to intermittent hypoxia promote visceral white adipose tissue inflammation in a murine model of severe sleep apnea: Effect of normoxic recovery. Sleep40:74. 10.1093/sleep/zsw074
54
GodslandI. F.GangarK.WaltonC.CustM. P.WhiteheadM. I.WynnV.et al. (1993). Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism42, 846–853. 10.1016/0026-0495(93)90058-V
55
GonzalezC.AlmarazL.ObesoA.RigualR. (1994). Carotid body chemoreceptors: from natural stimuli to sensory discharges. Physiologic. Rev.74:829. 10.1152/physrev.1994.74.4.829
56
González-OrtizM.Martínez-AbundisE.Balcázar-MuñozB. R.Pascoe-GonzálezS. (2000). Effect of sleep deprivation on insulin sensitivity and cortisol concentration in healthy subjects. Diabet. Nutri. Metabol.13, 80–83.
57
GoodpasterB. H.HarrisT. B.KrishnaswamiS.SchwartzA. V.ResnickH.KelleyD. E.et al. (2003). Tissue distribution and both type 2 diabetes and impaired glucose. Diabetes Care26:372. 10.2337/diacare.26.2.372
58
GreenbergH. E.SicaA.BatsonD.ScharfS. M. (1999). Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. J. Appl. Physiol.86, 298–305. 10.1152/jappl.1999.86.1.298
59
GrunsteinR. R.. (1996). Metabolic aspects of sleep apnea. Sleep19, 218–220. 10.1093/sleep/19.suppl_10.S218
60
GrunsteinR. R.HandelsmanD. J.LawrenceS. J.BlackwellC.CatersonI. D.SullivanC. E. (1989). Neuroendocrine dysfunction in sleep apnea: reversal by continuous positive airways pressure therapy. J. Clinic. Endocrinol. Metabol.68, 352–358. 10.1210/jcem-68-2-352
61
GündüzC.BasogluO. K.HednerJ.ZouD.BonsignoreM. R.HeinH.et al. (2018). Obstructive sleep apnoea independently predicts lipid levels: data from the European sleep apnea database. Respirology23, 1180–1189. 10.1111/resp.13372
62
HaarboJ.MarslewU.GotfredsenA.ChristiansenC. (1991). Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism40, 1323–1326. 10.1016/0026-0495(91)90037-W
63
HannhartB.PickettC. K.MooreL. G. (1990). Effects of estrogen and progesterone on carotid body neural output responsiveness to hypoxia. J. Appl. Physiol.68, 1909–1916. 10.1152/jappl.1990.68.5.1909
64
HarschI. A.KonturekP. C.KoebnickC.KuehnleinP. P.FuchsF. S.Pour SchahinS.et al. (2003). Leptin and ghrelin levels in patients with obstructive sleep apnoea: Effect of CPAP treatment. Euro. Respirat. J.22, 251–257. 10.1183/09031936.03.00010103
65
HarschI. A.SchahinS. P.BrücknerK.Radespiel-TrögerM.FuchsF. S.HahnE. G.et al. (2004). The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration71, 252–259. 10.1159/000077423
66
HeinzerR.VatS.Marques-VidalP.Marti-SolerH.AndriesD.TobbackN.et al. (2015). Prevalence of sleep-disordered breathing in the general population: THE HypnoLaus study. Lancet Respirat. Med.3, 310–318. 10.1016/S2213-2600(15)00043-0
67
HuangT.LinB. M.MarktS. C.StampferM. J.LadenF.HuF. B.et al. (2018). Sex differences in the associations of obstructive sleep apnoea with epidemiological factors. Euro. Respirat. J.51, 1–10. 10.1183/13993003.02421-2017
68
HudgelD. W.. (2016). Sleep apnea severity classification revisited. Sleep39, 1165–1166. 10.5665/sleep.5776
69
IgarashiN.TatsumiK.NakamuraA.SakaoS.TakiguchiY.NishikawaT.et al. (2003). Plasma Orexin-A levels in obstructive sleep apnea-hypopnea syndrome. Chest124, 1381–1385. 10.1378/chest.124.4.1381
70
IpL. B.NgM. M. T.LamW. K.TsangK. W. T.LamK. S. L. (2002). Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respirat. Critic. Care Med.165, 670–676. 10.1164/ajrccm.165.5.2103001
71
IpM. S. M.LamK. S. L.HoC. M.TsangK. W. T.LamW. (2000). Serum leptin and vascular risk factors in obstructive sleep apnea. Chest118, 580–586. 10.1378/chest.118.3.580
72
IturriagaR.. (2018). Translating carotid body function into clinical medicine. J. Physiol.596, 3067–3077. 10.1113/JP275335
73
JayaramanG.MajidH.SuraniS.KaoC.SubramanianS. (2011). Influence of gender on continuous positive airway pressure requirements in patients with obstructive sleep apnea syndrome. Sleep Breath.15, 781–784. 10.1007/s11325-010-0436-2
74
Jean-LouisG.ZiziF.ClarkL. T.BrownC. D.McFarlaneS. I. (2008). Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J. Clinic. Sleep Med.4, 261–272. 10.5664/jcsm.27191
75
JinS.JiangS.HuA. (2018). Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath.22, 841–851. 10.1007/s11325-018-1625-7
76
JosephT.Vincent BehanM.KinkeadR. (2013). Sex, hormones, and stress: how they impact development and function of the carotid bodies and related reflexes. Respirat. Physiol. Neurobiol.185, 75–86. 10.1016/j.resp.2012.07.001
77
JosephV.DoanV. D.MorencyC. E.LajeunesseY.BairamA. (2006). Expression of sex-steroid receptors and steroidogenic enzymes in the carotid body of adult and newborn male rats. Brain Res. 1, 71–82. 10.1016/j.brainres.2005.12.075
78
JosephV.LaouafaS.MarcouillerF.RousselD.PialouxV.BairamA. (2020). Progesterone decreases apnoea and reduces oxidative stress induced by chronic intermittent hypoxia in ovariectomized female rats. Experiment. Physiol.105, 1025–1034. 10.1113/EP088430
79
JosephV.NianeL. M.BairamA. (2012). Antagonism of progesterone receptor suppresses carotid body responses to hypoxia and nicotine in rat pups. Neuroscience207, 103–109. 10.1016/j.neuroscience.2012.01.041
80
KanayaA. M.HerringtonD.VittinghoffE.LinF.GradyD.BittnerV.et al. (2003). Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Annal. Intern. Med.138, 1–9. 10.7326/0003-4819-138-1-200301070-00005
81
KapásL.HongL.CadyA. B.OppM. R.SeyerM.KruegerJ. M. (1992). Somnogenic, pyrogenic and anorectic activities of tumor necrosis factor-a and TNF-a. Fragments. 12, 708–715. 10.1152/ajpregu.1992.263.3.R708
82
KapsimalisF.KrygerM. H. (2002). Gender and obstructive sleep apnea syndrome, part 2: Mechanisms. Sleep25, 499–506. 10.1093/sleep/25.5.497
83
KaracaZ.IsmailogullariS.KorkmazS.CakirI.AksuM.BaydemirR.et al. (2013). Obstructive sleep apnoea syndrome is associated with relative hypocortisolemia and decreased hypothalamo-pituitary-adrenal axis response to 1 and 250μg ACTH and glucagon stimulation tests. Sleep Med.14, 160–164. 10.1016/j.sleep.2012.10.013
84
KimJ. H.MeyersM. S.KhuderS. S.AbdallahS. L.MuturiH. T.RussoL.et al. (2014). Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol. Metabol.3, 177–190. 10.1016/j.molmet.2013.12.009
85
KohlerM.AyersL.PepperellJ. C. T.PackwoodK. L.FerryB.CrosthwaiteN.et al. (2009). Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax64, 67–73. 10.1136/thx.2008.097931
86
KritikouI.BastaM.VgontzasA. N.PejovicS.LiaoD.BixlerE. O.et al. (2016). Sleep apnoea and the hypothalamic–pituitary–adrenal axis in men and women: effects of continuous positive airway pressure. Euro. Respirat. J.47, 531–540. 10.1183/13993003.00319-2015
87
KritikouI.BastaM.VgontzasA. N.PejovicS.LiaoD.TsaoussoglouM.et al. (2014). Sleep apnoea, sleepiness, inflammation and insulin resistance in middle-aged males and females. Euro. Respirat. J.43, 145–155. 10.1183/09031936.00126712
88
KrystalA. D.. (2003). Insomnia in women. Clinic. Cornerstone5, 41–50. 10.1016/S1098-3597(03)90034-2
89
KrystalA. D.EdingerJ.MarshG. R. (1998). Sleep in peri-menopausal. Sleep Med. Rev.2, 243–253. 10.1016/S1087-0792(98)90011-9
90
LamJ. C. M.YanC. S. W.LaiA. Y. K.TamS.FongD. Y. T.LamB.et al. (2009). Determinants of daytime blood pressure in relation to obstructive sleep apnea in men. Lung187, 291–298. 10.1007/s00408-009-9161-7
91
LavieL.. (2015). Oxidative stress in obstructive sleep apnea and intermittent hypoxia—Revisited—The bad ugly and good: Implications to the heart and brain. Sleep Med. Rev.20, 27–45. 10.1016/j.smrv.2014.07.003
92
LevinsonP. D.MillmanR. P. (1991). Causes and consequences of blood pressure alterations in obstructive sleep apnea. Archiv. Intern. Med.151, 455–462. 10.1001/archinte.1991.00400030025005
93
MårinP.. (1998). Effects of androgens in men with the metabolic syndrome. Aging Male1, 129–136. 10.3109/13685539809148611
94
MårinP.HolmängS.JönssonL.SjöströmL.KvistH.HolmG.et al. (1992). The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord.12, 991–997.
95
MansonJ. A. E.ChlebowskiR. T.StefanickM. L.AragakiA. K.RossouwJ. E.PrenticeR. L.et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials. JAMA—J. Am. Med. Assoc.310, 1353–1368. 10.1001/jama.2013.278040
96
MarcusN. J.LiY. L.BirdC. E.SchultzH. D.MorganB. J. (2010). Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor. Respirat. Physiol. Neurobiol.171, 36–45. 10.1016/j.resp.2010.02.003
97
MargolisK. L.BondsD. E.RodaboughR. J.TinkerL.PhillipsL. S.AllenC.et al. (2004). Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women's health initiative hormone trial. Diabetologia47, 1175–1187. 10.1007/s00125-004-1448-x
98
MarklundM.StenlundH.FranklinK. A. (2004). Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. Chest125, 1270–1278. 10.1378/chest.125.4.1270
99
Martinez-CeronE.BarquielB.BezosA. M.CasitasR.GaleraR.Garcia-BenitoC.et al. (2016). Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes a randomized clinical trial. Am. J. Respirat. Critic. Care Med.194, 476–485. 10.1164/rccm.201510-1942OC
100
MartinsF. O.SacramentoJ. F.OleaE.MeloB. F.Prieto-LloretJ.ObesoA.et al. (2021). Chronic intermittent hypoxia induces early-stage metabolic dysfunction independently of adipose tissue deregulation. Antioxidants10, 1–17. 10.3390/antiox10081233
101
Mauvais-JarvisF.. (2016). Role of sex steroids in β cell function, growth, and survival. Trends Endocrinol. Metabol.27, 844–855. 10.1016/j.tem.2016.08.008
102
Mauvais-JarvisF.MansonJ. A. E.StevensonJ. C.FonsecaV. A. (2017). Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocr. Rev.38, 173–188. 10.1210/er.2016-1146
103
MichelsG.HoppeU. C. (2008). Rapid actions of androgens. Front. Neuroendocrinol.29:4. 10.1016/j.yfrne.2007.08.004
104
MirasA. D.KamockaA.PatelD.DexterS.FinlayI.HopkinsJ. C.et al. (2018). Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surg. Obesit. Relat. Dis.14, 1033–1040. 10.1016/j.soard.2018.02.012
105
MokhlesiB.GrimaldiD.BeccutiG.AbrahamV.WhitmoreH.DelebecqueF.et al. (2016). Effect of one week of 8-hour nightly continuous positive airway pressure treatment of obstructive sleep apnea on glycemic control in type 2 diabetes: a proof-of-concept study. Am. J. Respirat. Critic. Care Med.194, 516–519. 10.1164/rccm.201602-0396LE
106
MurphyA. M.ThomasA.CrinionS. J.KentB. D.TambuwalaM. M.FabreA.et al. (2017). Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation. Euro. Respirat. J.49:4. 10.1183/13993003.01731-2016
107
MuscelliE.CamastraS.CatalanoC.GalvanA. Q.CiociaroD.BaldiS.et al. (1997). Metabolic and cardiovascular assessment in moderate obesity: effect of weight loss. J. Clinic. Endocrinol. Metabol.82, 2937–2943. 10.1210/jcem.82.9.4228
108
NakamuraT.ChinK.ShimizuK.KitaH.MishimaM.NakamuraT.et al. (2001). Acute effect of nasal continuous positive airway pressure therapy on the systemic immunity of patients with obstructive sleep apnea syndrome. Sleep24, 545–553. 10.1093/sleep/24.5.545
109
NarkiewiczK.SomersV. K. (1999). Interactive effect of heart rate and muscle sympathetic nerve activity on blood pressure. Circulation100, 2514–2518. 10.1161/01.CIR.100.25.2514
110
NetzerN. C.EliassonA. H.StrohlK. P. (2003). Women with sleep apnea have lower levels of sex hormones. Sleep Breath.7, 25–29. 10.1007/s11325-003-0025-8
111
NewmanA. B.FosterG.GivelberR.NietoF. J.RedlineS.YoungT. (2005). Progression and regression of sleep-disordered breathing with changes in weight: the sleep heart health study. Archiv. Intern. Med.165, 2408–2413. 10.1001/archinte.165.20.2408
112
NilssonS.Mäkel,äS.TreuterE.TujagueM.ThomsenJ.AnderssonG.et al. (2001). Mechanisms of estrogen action. Physiol. Rev.81, 1535–1565. 10.1152/physrev.2001.81.4.1535
113
O'DonnellC. P.SchaubC. D.HainesA. S.BerkowitzD. E.TankersleyC. C.SchwartzA. R.et al. (1999). Leptin prevents respiratory depression in obesity. Am. J. Respirat. Critic. Care Med.159, 1477–1484. 10.1164/ajrccm.159.5.9809025
114
OleaE.AgapitoM. T.Gallego-MartinT.RocherA.Gomez-NiñoA.ObesoA.et al. (2014). Intermittent hypoxia and diet-induced obesity: effects on oxidative status, sympathetic tone, plasma glucose and insulin levels, and arterial pressure. J. Appl. Physiol.117, 706–719. 10.1152/japplphysiol.00454.2014
115
OppM. R.KapásL.TothL. A. (1992). Cytokine Involvement in the Regulation of Sleep. Proceed. Soc. Experiment. Biol. Med.201, 16–27. 10.3181/00379727-201-43474
116
OrffH.MeliskaC.MartinezF.ParryB. (2014). The influence of sex and gonadal hormones on sleep disorders. ChronoPhysiol. Therap.15:44667. 10.2147/CPT.S44667
117
ÖztürkL.ÜnalM.TamerL.ÇelikogluF. (2003). The association of the severity of obstructive sleep apnea with plasma leptin levels. Archiv. Otolaryngol. Head Neck Surg.129, 538–540. 10.1001/archotol.129.5.538
118
PamidiS.WroblewskiK.StepienM.Sharif-SidiK.KilkusJ.WhitmoreH.et al. (2015). Eight hours of nightly continuous positive airway pressure treatment of obstructive sleep apnea improves glucose metabolism in patients with prediabetes: a randomized controlled trial. Am. J. Respirat. Critic. Care Med.192, 96–105. 10.1164/rccm.201408-1564OC
119
PanareeB.ChantanaM.WasanaS.ChairatN. (2011). Effects of obstructive sleep apnea on serum brain-derived neurotrophic factor protein, cortisol, and lipid levels. Sleep Breath.15, 649–656. 10.1007/s11325-010-0415-7
120
PasqualiR.CasimirriF.MelchiondaN.FabbriR.CapelliM.PlatèL.et al. (1988). Weight loss and sex steroid metabolism in massively obese man. J. Endocrinol. Investigat.11, 205–210. 10.1007/BF03350136
121
PengY. J.NanduriJ.YuanG.WangN.DenerisE.PendyalaS.et al. (2009). NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. J. Neurosci.29, 4903–4910. 10.1523/JNEUROSCI.4768-08.2009
122
PengY. J.OverholtJ. L.KlineD.KumarG. K.PrabhakarN. R. (2003). Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. Proceed. Nat. Acad. Sci. USA100, 10073–10078. 10.1073/pnas.1734109100
123
PhillipsB. G.KatoM.NarkiewiczK.ChoeI.SomersV. K. (2000). Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circulat. Physiol.279, 234–237. 10.1152/ajpheart.2000.279.1.H234
124
PillarG.ShehadehN. (2008). Abdominal fat and sleep apnea: the chicken or the egg?Diabetes Care31, S303–S309. 10.2337/dc08-s272
125
PolotskyV. Y.LiJ.PunjabiN. M.RubinA. E.SmithP. L.SchwartzA. R.et al. (2003). Intermittent hypoxia increases insulin resistance in genetically obese mice. J. Physiol.552, 253–264. 10.1113/jphysiol.2003.048173
126
PrabhakarN. R.KumarG. K. (2010). Mechanisms of sympathetic activation and blood pressure elevation by intermittent hypoxia. Respirat. Physiol. Neurobiol.174, 156–161. 10.1016/j.resp.2010.08.021
127
PrabhakarN. R.PengY. J.JaconoF. J.KumarG. K.DickT. E. (2005). Cardiovascular alterations by chronic intermittent hypoxia: importance of carotid body chemoreflexes. Clinic. Experiment. Pharmacol. Physiol.32, 447–449. 10.1111/j.1440-1681.2005.04209.x
128
PunjabiN. M.. (2008). The epidemiology of adult obstructive sleep apnea. Proc. Am. Thorac. Soc.5, 136–143. 10.1513/pats.200709-155MG
129
PunjabiN. M.SorkinJ. D.KatzelL. I.GoldbergA. P.SchwartzA. R.SmithP. L. (2002). Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am. J. Respirat. Critic. Care Med.165, 677–682. 10.1164/ajrccm.165.5.2104087
130
RamarK.CaplesS. M. (2011). Vascular changes, cardiovascular disease and obstructive sleep apnea. Fut. Cardiol.7, 241–249. 10.2217/fca.10.123
131
RedlineS.KumpK.TishlerP. V.BrownerI.FerretteV. (1994). Gender differences in sleep disordered breathing in a community-based sample. Am. J. Respirat. Critic. Care Med.149, 722–726. 10.1164/ajrccm.149.3.8118642
132
ReyS.Del RioR.AlcayagaJ.IturriagaR. (2004). Chronic intermittent hypoxia enhances cat chemosensory and ventilatory responses to hypoxia. J. Physiol.560, 577–586. 10.1113/jphysiol.2004.072033
133
RibeiroM. J.SacramentoJ. F.Gallego-MartinT.OleaE.MeloB. F.GuarinoM. P.et al. (2018). High fat diet blunts the effects of leptin on ventilation and on carotid body activity. J. Physiol.596, 3187–3199. 10.1113/JP275362
134
RibeiroM. J.SacramentoJ. F.GonzalezC.GuarinoM. P.MonteiroE. C.CondeS. V. (2013). Carotid body denervation prevents the development of insulin resistance and hypertension induced by hypercaloric diets. Diabetes62, 2905–2916. 10.2337/db12-1463
135
RyanS.TaylorC. T.McNicholasW. T. (2005). Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation112, 2660–2667. 10.1161/CIRCULATIONAHA.105.556746
136
SaaresrantaT.PoloO. (2003). Sleep-disordered breathing and hormones. Euro. Respirat. J.22, 161–172. 10.1183/09031936.03.00062403
137
SacramentoF. O.RodriguesT.MatafomeP.RibeiroM. J.OleaE.CondeS. V. (2020). A2 Adenosine receptors mediate whole-body insulin sensitivity in a prediabetes animal model: primary effects on skeletal muscle. Front. Endocrinol.20:262. 10.3389/fendo.2020.00262
138
SacramentoJ. F.ChewD. J.MeloB. F.Doneg,áM.DopsonW.GuarinoM. P.et al. (2018). Bioelectronic modulation of carotid sinus nerve activity in the rat: a potential therapeutic approach for type 2 diabetes. Diabetologia61, 700–710. 10.1007/s00125-017-4533-7
139
SacramentoJ. F.RibeiroM. J.RodriguesT.OleaE.MeloB. F.GuarinoM. P.et al. (2017). Functional abolition of carotid body activity restores insulin action and glucose homeostasis in rats: key roles for visceral adipose tissue and the liver. Diabetologia60, 158–168. 10.1007/s00125-016-4133-y
140
SacramentoR.ibeiroM. J.RodriguesT.GuarinoM. P.DiogoL. N.SeiçaR.MonteiroE. C.et al. (2016). Insulin resistance is associated with tissue-specific regulation of HIF-1α and HIF-2α during mild chronic intermittent hypoxia. Respirat. Physiol. Neurobiol.228, 30–38. 10.1016/j.resp.2016.03.007
141
SainiJ.KriegerJ.BrandenbergerG.WittersheimG.SimonC.FolleniusM. (1993). Continuous positive airway pressure treatment. effects on growth hormone, insulin and glucose profiles in obstructive sleep apnea patients. Horm. Metabol. Res.25, 375–381. 10.1055/s-2007-1002123
142
SalpeterS. R.WalshJ. M. E.OrmistonT. M.GreyberE.BuckleyN. S.SalpeterE. E. (2006). Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabet. Obesit. Metabol.8, 538–554. 10.1111/j.1463-1326.2005.00545.x
143
SannerB. M.KollhosserP.BuechnerN.ZidekW.TepelM. (2004). Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Euro. Respirat. J.23, 601–604. 10.1183/09031936.04.00067804
144
ShaharE.RedlineS.YoungT.BolandL. L.BaldwinC. M.NietoF. J.et al. (2003). Hormone replacement therapy and sleep-disordered breathing. Am. J. Respirat. Critic. Care Med.167, 1186–1192. 10.1164/rccm.200210-1238OC
145
ShinM. K.YaoQ.JunJ. C.Bevans-FontiS.YooD. Y.HanW.et al. (2014). Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia. J. Appl. Physiol.117, 765–776. 10.1152/japplphysiol.01133.2013
146
ShipleyJ. E.SchteingartD. E.TandonR.StarkmanM. N. (1992). Sleep architecture and sleep apnea in patients with Cushing's disease. Sleep15, 514–518. 10.1093/sleep/15.6.514
147
SimpsonE. R.ClyneC.RubinG.WahC. B.RobertsonK.BrittK.et al. (2002). Aromatase—a brief overview. Ann. Rev. Physiol.64, 93–127. 10.1146/annurev.physiol.64.081601.142703
148
SkatrudJ. B.DempseyJ. A.KaiserD. G. (1978). Ventilatory response to medroxyprogesterone acetate in normal subjects: time course and mechanism. J. Appl. Physiol. Respirat. Environ. Exer. Physiol.44, 939–944. 10.1152/jappl.1978.44.6.939
149
SmithE. R.StefanickM. L.ClarkJ. T.DavidsonJ. M. (1992). Hormones and sexual behavior in relationship to aging in male rats. Horm. Behav.26, 110–135. 10.1016/0018-506X(92)90035-T
150
SmithS. S.ShenH.GongQ. H.ZhouX. (2007). Neurosteroid regulation of GABAA receptors: focus on the α4 and δ subunits. Pharmacol. Therapeut.116, 58–76. 10.1016/j.pharmthera.2007.03.008
151
SmurraM.PhilipP.TaillardJ.GuilleminaultC.BioulacB.GinH. (2001). CPAP treatment does not affect glucose-insulin metabolism in sleep apneic patients. Sleep Med.2, 207–213. 10.1016/S1389-9457(00)00079-4
152
SomersA. L.AbboudF. M. (1988). Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension11, 608–612. 10.1161/01.HYP.11.6.608
153
SomersV. K.DykenM. E.ClaryM. P.AbboudF. M. (1995). Sympathetic neural mechanisms in obstructive sleep apnea. J. Clinic. Investigat.96, 1897–1904. 10.1172/JCI118235
154
Späth-SchwalbeE.HansenK.SchmidtF.SchrezenmeierH.MarshallL.BurgerK.et al. (1998). Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clinic. Endocrinol. Metabol.83, 1573–1579. 10.1210/jc.83.5.1573
155
Stoffel-WagnerB.. (2001). Neurosteroid metabolism in the human brain. Euro. J. Endocrinol.145, 669–679. 10.1530/eje.0.1450669
156
TamisierR.PépinJ. L.RémyJ.BaguetJ. P.TaylorJ. A.WeissJ. W.et al. (2011). 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Euro. Respirat. J.37, 119–128. 10.1183/09031936.00204209
157
TaylorK. S.MuraiH.MillarP. J.HarukiN.KimmerlyD. S.MorrisB. L.et al. (2016). Arousal from sleep and sympathetic excitation during wakefulness. Hypertension68, 1467–1474. 10.1161/HYPERTENSIONAHA.116.08212
158
TianoJ. P.Mauvais-JarvisF. (2012). Importance of oestrogen receptors to preserve functional β-cell mass in diabetes. Nat. Rev. Endocrinol.8, 342–351. 10.1038/nrendo.2011.242
159
UrsavasA.IlcolY. O.NalciN.KaradagM.EgeE. (2010). Ghrelin, leptin, adiponectin, and resistin levels in sleep apnea syndrome: role of obesity. Ann. Thoracic Med.5, 161–165. 10.4103/1817-1737.65050
160
Van CauterE.SpiegelK. (1997). Hormones and metabolism during sleep. Monogr. Clin. Neurosci.15, 144–174. 10.1159/000061553
161
Van EyckA.Van HoorenbeeckK.De WinterB. Y.Van GaalL.De BackerW.VerhulstS. L. (2017). Sleep-disordered breathing, systemic adipokine secretion, and metabolic dysregulation in overweight and obese children and adolescents. Sleep Med.30, 52–56. 10.1016/j.sleep.2015.11.014
162
VasudevanN.PfaffD. W. (2008). Non-genomic actions of estrogens and their interaction with genomic actions in the brain. Front. Neuroendocrinol.29, 238–257. 10.1016/j.yfrne.2007.08.003
163
VecchieriniM. F.AttaliV.ColletJ. M.d'OrthoM. P.GoutorbeF.KerbratJ. B.et al. (2019). Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. Sleep Breath.23, 837–848. 10.1007/s11325-018-1766-8
164
VgontzasA.ChrousosG. (2002). Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinol. Metabol. Clinic. N A31, 15–36. 10.1016/S0889-8529(01)00005-6
165
VgontzasA. N.BixlerE. O.ChrousosG. P. (2003). Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J. Intern. Med.254, 32–44. 10.1046/j.1365-2796.2003.01177.x
166
VgontzasA. N.PejovicS.ZoumakisE.LinH. M.BentleyC. M.BixlerE. O.et al. (2007). Hypothalamic-pituitary-adrenal axis activity in obese men with and without sleep apnea: Effects of continuous positive airway pressure therapy. J. Clinic. Endocrinol. Metabol.92, 4199–4207. 10.1210/jc.2007-0774
167
VgontzasP.apanicolaouD. A.BixlerE. O.HopperK.LotsikasA.LinH. M.KalesA.et al. (2000). Sleep apnea and daytime sleepiness and fatigue: Relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clinic. Endocrinol. Metabol.85, 1151–1158. 10.1210/jcem.85.3.6484
168
VgontzasT.BixlerE. O.ChrousosG. P. (2005). Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med. Rev.9, 211–224. 10.1016/j.smrv.2005.01.006
169
VgontzasZ.oumakisE.BixlerE. O.LinH. M.CollinsB.BastaM.PejovicS.et al. (2008). Selective effects of CPAP on sleep apnoea-associated manifestations. Euro. J. Clinic. Investigat.38, 585–595. 10.1111/j.1365-2362.2008.01984.x
170
WangN.KhanS. A.PrabhakarN. R.NanduriJ. (2013). Impaired pancreatic beta cell function by chronic intermittent hypoxia. Exp Physiol.98, 1376–1385. 10.1113/expphysiol.2013.072454
171
WeinstockT. G.WangX.RueschmanM.Ismail-BeigiF.AylorJ.BabineauD. C.et al. (2012). A controlled trial of CPAP therapy on metabolic control in individuals with impaired glucose tolerance and sleep apnea. Sleep35, 617–625. 10.5665/sleep.1816
172
WrayC. M.ThalerE. R. (2016). Hypoglossal nerve stimulation for obstructive sleep apnea: a review of the literature. World J. Otorhinolaryngol. Head Neck Surg.2, 230–233. 10.1016/j.wjorl.2016.11.005
173
YamazakiH.HajiA.OhiY.TakedaR. (2005). Effects of progesterone on apneic events during behaviorally defined sleep in male rats. Life Sci.78, 383–388. 10.1016/j.lfs.2005.04.062
174
YangD.LiuZ.YangH.LuoQ. (2013). Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep. Sleep Breath.17, 33–38. 10.1007/s11325-012-0680-8
175
YosunkayaS.OkurH. K.CanÜ.ZamaniA.KutluR. (2015). Impact of continuous positive airway pressure treatment on leptin levels in patients with obstructive sleep apnea syndrome. Metabol. Syndr. Relat. Disord.13, 272–277. 10.1089/met.2014.0161
176
YoungT.FinnL.AustinD.PetersonA. (2003). Menopausal status and sleep-disordered breathing in the wisconsin sleep cohort study. Am. J. Respirat. Critic. Care Med.167, 1181–1185. 10.1164/rccm.200209-1055OC
177
YoungT.PaltaM.DempseyJ.SkatrudJ.WeberS.BadrS. (1993). The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med.328, 1230–1235. 10.1056/NEJM199304293281704
178
YukawaK.InoueY.YagyuH.HasegawaT.KomadaY.NambaK.et al. (2009). Gender differences in the clinical characteristics among japanese patients with obstructive sleep apnea syndrome. Chest135, 337–343. 10.1378/chest.08-1414
179
ZoccalD. B.SimmsA. E.BonagambaL. G. H.BragaV. A.PickeringA. E.PatonJ. F. R.et al. (2008). Increased sympathetic outflow in juvenile rats submitted to chronic intermittent hypoxia correlates with enhanced expiratory activity. J. Physiol.586, 3253–3265. 10.1113/jphysiol.2008.154187
Summary
Keywords
gender, obstructive sleep apnea, metabolic dysfunction, sex hormones, chronic intermittent hypoxia
Citation
Martins FO and Conde SV (2021) Gender Differences in the Context of Obstructive Sleep Apnea and Metabolic Diseases. Front. Physiol. 12:792633. doi: 10.3389/fphys.2021.792633
Received
10 October 2021
Accepted
17 November 2021
Published
14 December 2021
Volume
12 - 2021
Edited by
Vincent Joseph, Laval University, Canada
Reviewed by
Ying-Jie Peng, University of Chicago, United States; Eduardo Colombari, Universidade Estadual Paulista, Brazil
Updates
Copyright
© 2021 Martins and Conde.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fátima O. Martins fatima.martins@nms.unl.ptSílvia V. Conde silvia.conde@nms.unl.pt
This article was submitted to Respiratory Physiology, a section of the journal Frontiers in Physiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.